C. difficile GDH antibodies
NEW from BBI Solutions, C. Difficile GDH antibodies sold under license from bioMérieux. The antibodies are from clones used in bioMerieux’s commercial assays, and are manufactured under cGMP conditions at BBI’s Maine facility.
Customers can be confident in sampling this performance tested matched pair to C. difficile GDH, an enzyme broadly used as a primary screen for C. difficile infection. By manufacturing the antibodies in-house, BBI can ensure secure supply with increased batch-to-batch consistency, customised production timelines and parameters to meet customer validation needs.
Figure 1: A colourimetric sandwich ELISA demonstrating sensitive detection of C. difficile recombinant GDH (rGDH) protein. Data generated using three lots of each antibody demonstrating assay robustness and lot-to-lot reproducibility of the antibody productions.
Use in Assays
MAB294P is manufactured from a licensed cell line of clone 9C11B4
MAB295P is manufactured from a licensed cell line of clone 3D1G11
Clones 9C11B4 and 3D1G11 have been successfully used in commercialised bioMérieux immunoassay products* in which 9C11B4 was the capture antibody and clone 3D1G11 was the detector antibody.
* VIDAS and/or VIKIA and/or BIONEXIA
Maximise your chances of developing a successful C. difficile GDH assay:
+ Antibody clones used as matched pair in commercialised bioMerieux assays – proven performance
+ Manufactured in-house at BBI for security of supply
+ cGMP production and quality management for increased batch-to-batch consistency
+ Suite of reagents for your C. difficile assay needs